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line bonds (30). E. coli K-12 encodes at least four periplasmic
enzymes in these families: the cyclophilin PpiA (20), the
FK506-binding protein-like isomerase FkpA (13), and two parvulin domain-containing isomerases, SurA and PpiD (7, 8, 19).
Growth of E. coli K-12 under laboratory conditions was not
affected when all four PPIase genes were inactivated (17).
SurA possesses periplasmic chaperone activity that localizes
not to its two parvulin-like PPIase domains but to its N-terminal substrate-binding domain (3, 4, 12, 31). The peptide substrates of SurA are not precisely known, but it has been previously shown that mutation in surA in E. coli K-12 results in
reduced amounts of OmpA and LamB in the outer membrane
(19). In addition, maturation of the type 1 pilus usher FimD is
impaired in the surA mutant of E. coli K-12 carrying a plasmid
containing the fim operon. FimD is also unstable when expressed from its native chromosomal location in the surA mutant of UPEC strain UTI89 (17).
Recently, it was shown that uropathogenic strains of E. coli
are able to suppress bladder epithelial cytokine responses in
vitro (15), a property that may facilitate early IBC formation.
This effect was possibly related to lipopolysaccharide (LPS)
structure, as mutations within the LPS biosynthetic operons rfa
and rfb (resulting in lack of O antigen) led to loss of suppression. In addition, inactivation of surA led to abrogation of this
anti-inflammatory effect, while its LPS reactivity with O typing
antiserum was intact, suggesting that SurA participates in the
maturation of an additional surface-expressed or secreted factor responsible for UPEC suppression of cytokine production
by epithelial cells.
Here, we investigated the steps in IBC maturation that were
supported by SurA. Inactivation of surA in UPEC resulted in
deficient binding and invasion of bladder epithelial cells, with
a disproportionate effect on invasion. In addition, SurA was

Urinary tract infections (UTI) represent a significant cause
of morbidity and are most frequently caused by uropathogenic
Escherichia coli (UPEC) (10). The ability of UPEC to establish
infection in the urinary tract is most closely linked to the
production of adhesive pili that interact with receptors on
urinary epithelial cells. P pili are produced by pyelonephritic
strains of UPEC, bind to globoseries glycolipids present on the
kidney epithelium, and are critical for the establishment of
pyelonephritis (27). Production of type 1 pili is required for
UPEC to establish cystitis (11, 14, 29). These fibers bind to
mannosylated uroplakin molecules on the surfaces of superficial facet cells of the bladder epithelium, mediating bacterial
entry (21–23, 32). Once inside facet cells, UPEC multiplies and
forms morphologically distinct organized colonies called intracellular bacterial communities (IBCs), which provide a safe
haven from effectors of host immunity. Initially, IBCs are loose
collections of rod-shaped bacteria that soon mature into coccoid organisms with a distinct, tightly packed architecture (16).
In response to unknown signals, bacteria at the IBC periphery
either adopt a filamentous phenotype or detach from the community, flux from facet cells, and reestablish infection in naive
epithelial cells, eventually forming a quiescent reservoir undetected by host immune surveillance (24). Type 1 pili are required for the initial binding and invasion events; however,
little is known about the molecular basis of IBC maturation
subsequent to invasion.
The peptidyl-prolyl isomerases (PPIases) include at least
three related families of proteins in eukaryotes and prokaryotes that catalyze the cis-trans conversion of peptidyl pro-
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Escherichia coli is the most common cause of community-acquired urinary tract infection (UTI). During
murine cystitis, uropathogenic E. coli (UPEC) utilizes type 1 pili to bind and invade superficial bladder
epithelial cells. UPEC then replicates within to form intracellular bacterial communities (IBCs), a process
whose genetic determinants are as yet undefined. In this study, we investigated the role of SurA in the UPEC
pathogenic cascade. SurA is a periplasmic prolyl isomerase/chaperone that facilitates outer membrane protein
biogenesis and pilus assembly in E. coli. Invasion into bladder epithelial cells was disproportionately reduced
when surA was genetically disrupted in the UPEC strain UTI89, demonstrating that binding alone is not
sufficient for invasion. In a murine cystitis model, UTI89 surA::kan was unable to persist in the urinary tract.
Complementation of UTI89 surA::kan with a plasmid (pDH15) containing surA under the control of an
arabinose-inducible promoter restored in vivo binding and invasion events. However, the absence of arabinose
within the mouse bladder resulted in depletion of SurA after invasion of the bacteria into the superficial
epithelial cells. Under these conditions, invasion by UTI89/pDH15 surA::kan was normal, but in contrast to
UTI89, UTI89/pDH15 surA::kan formed intracellular collections that contained fewer bacteria, were loosely
organized, and lacked the normal transition to a densely packed, coccoid morphology. Our data argue that
SurA is required within bladder epithelial cells for UPEC to undergo the morphological changes that underlie
IBC maturation and completion of the UTI pathogenic cascade.
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TABLE 1. Hemagglutination titers
HA titer
Strain

UTI89
UTI89 surA::kan
UTI89/pDH15 surA::kan
a

No mannose

⫹2% mannose

1:512
1:4a
1:256–1:512

0
0
0

Significantly different from wild-type UTI89 (P ⬍ 0.001 by paired t test).

(Carl Zeiss Inc.). Negative-stain electron microscopy (EM) was performed as
described previously (17). For immunogold EM, washed bacteria were adsorbed
to Formvar/carbon-coated grids, incubated sequentially with primary antiFimHA antibody and secondary AlexaFluor 488-conjugated anti-rabbit IgG, and
washed twice with distilled water before staining with 1% aqueous uranyl acetate.
Samples were viewed on a 1200EX transmission electron microscope (JEOL
USA, Peabody, MA).
Ex vivo gentamicin protection assay. Eight-week-old C3H/HeN female mice
(in experimental groups of four to six mice) were inoculated with ⬃107 CFU of
the strains listed in Table 1 as described above. One hour after infection, mice
were sacrificed and bladders were removed in sterile fashion. Bladders were
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shown to be required for intracellular growth and IBC maturation during murine cystitis.
MATERIALS AND METHODS
Bacterial strains and plasmids. The UPEC strain UTI89 was obtained from a
patient with cystitis (24), and construction of the surA mutant was previously
described (18). Plasmid pAER1 (kind gift from T. Silhavy) contains the surA
coding sequence under the control of the arabinose-inducible ParaBAD promoter
(26). Plasmid pDH15 was constructed by MluI excision of the kanamycin resistance gene from pcomGFP (6) followed by ligation into this site of a 2.9-kb
araC-ParaBAD-surA fragment from pAER1 flanked by AscI sites. pDH15 retains
GFPmut3 under the control of the Ptac promoter. For all assays, bacteria were
grown overnight in standing Luria broth culture with appropriate antibiotics at
37°C. Induction of surA from pDH15 was achieved by adding L-arabinose at
concentrations up to 0.2%.
In vitro HA, binding, and invasion. Hemagglutination (HA) assays were performed as described previously (19). Cultured 5637 human bladder epithelial
cells (ATCC HTB-9) were obtained from the American Type Culture Collection
(Manassas, VA) and grown in RPMI 1640 supplemented with 10% fetal bovine
serum (Sigma-Aldrich Co., St. Louis, MO) at 37°C in a humidified atmosphere
of 95% air and 5% CO2. Forty-eight hours prior to assay, cells were detached
with 0.05% trypsin–0.02% EDTA, centrifuged, resuspended in fresh medium,
and allocated to wells of sterile 24-well tissue culture plates. On the day of assay,
confluent monolayers were washed once with sterile phosphate-buffered saline
(PBS), and fresh medium was applied prior to infection with 107 CFU/ml of the
strains indicated in Table 1 and Fig. 1. Quantitative determination of bound and
invaded bacteria was performed as previously described (21).
Murine cystitis and confocal microscopy. The murine cystitis model has been
described in detail (23). Briefly, 8-week-old female C3H/HeN mice fed arabinose-free chow were anesthetized and transurethrally inoculated with 107 CFU
of the UPEC strains listed in Table 1. At the time points indicated in Fig. 4, 5,
and 6, mice were sacrificed and bladders were removed in sterile fashion. For
assessment of bacterial titers, groups of five mice were infected with each strain.
The bladders were homogenized in PBS with 0.1% Triton X-100 and serial
dilutions plated onto Luria-Bertani (LB) agar; the lower limit of detection is
assessed to be 10 CFU/bladder. For lacZ staining (25), groups of three or four
mice were infected with the UPEC strains; bladders were stretched, fixed for 30
min in 10% neutral buffered formalin (NBF), washed with lacZ wash buffer (PBS
with 0.01 M MgCl2, 0.01% sodium deoxycholate, and 0.02% Igepal [{octylphenoxy}polyethoxyethanol] CA-640), incubated in lacZ stain (lacZ wash buffer with 1 mg/ml
X-Gal [5-bromo-4-chloro-3-indolylphosphate], 5 mM potassium ferrocyanide,
and 5 mM potassium ferricyanide) for 16 h, washed three times in PBS, and
photographed by light microscopy in whole mount for enumeration of spots
representing IBCs. Bladders were then further fixed in 10% NBF overnight and
embedded in paraffin. Sections were deparaffinized and stained with hematoxylin
and eosin for light microscopy. For confocal microscopy, freshly harvested bladders from experimental groups of three or four mice were stretched under PBS,
fixed with 3% paraformaldehyde for 1 h, stained briefly with SYTO 61 red
fluorescent nucleic acid stain (Molecular Probes, Eugene, OR), washed five
times with PBS, mounted on glass slides under ProLong antifade reagent (Molecular Probes), and then viewed using the LSM510 Meta laser scanning confocal
microscope (Carl Zeiss Inc., Thornwood, NY). Experiments were repeated at
least three times.
Fluorescence and EM. For immunofluorescence, bacteria were washed in PBS
and incubated for 1 h with mouse antibody raised to the FimH adhesin domain
(anti-FimHA) (MedImmune Inc., Gaithersburg, MD). Cells were washed several
times in PBS and incubated with AlexaFluor 488-conjugated anti-mouse immunoglobulin G (IgG; Molecular Probes). After additional PBS washes, cells were
applied to a glass slide and viewed using the Axioskop 2 fluorescence microscope

FIG. 1. Mutation in surA confers a disproportionate effect on bacterial invasion in vitro. Monolayers of cultured 5637 bladder epithelial
cells were infected with wild-type UTI89, UTI89 surA::kan, or UTI89
surA::kan complemented with plasmid pAER1, and bacteria bound (as
a proportion of input bacteria) and invaded (as a proportion of bound
bacteria) were quantified. The surA mutant demonstrates reduced
binding (A) and an additive defect in invasion capacity (B) (*, P ⬍
0.005 versus wild type). Experiments were repeated at least three times
with similar results.
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splayed and washed three times in 500 ml sterile PBS each time; these collected
washes represent luminal bacteria. Bladders were then incubated for 90 min at
37°C with 100 g/ml gentamicin to kill adherent extracellular bacteria. After this
incubation, bladders were washed three times in 1 ml fresh sterile PBS. Bladders
were homogenized in 1 ml PBS with 0.01% Triton X-100 (this lysate, representing invaded bacteria, was termed the intracellular fraction). Undiluted and 100fold-diluted samples of luminal and intracellular fractions were plated to LB agar
and incubated overnight at 37°C for colony enumeration.

RESULTS
Binding and invasion are deficient in surA mutant UPEC.
The ability of UPEC to bind and invade human cultured bladder epithelial cell monolayers is conferred by type 1 pili and,
more specifically, by the type 1 tip adhesin FimH (21). Our
recent work demonstrated that inactivation of surA in E. coli
K-12 or in UPEC resulted in significantly decreased levels of
the type 1 pilus usher FimD in the outer membrane (17). We
therefore evaluated the in vitro type 1 pilus-dependent functions of the UPEC surA mutant. UTI89 surA::kan demonstrated reduced HA of guinea pig erythrocytes (Table 1); the
residual HA was inhibited by the addition of 2% methyl-␣-Dmannopyranoside. Correspondingly, the surA mutant exhibited
a 10-fold decrease in binding to cultured 5637 bladder epithelial cells. Surprisingly, when internalized bacteria were counted
relative to bound bacteria, we found a disproportionate effect

on invasion in the surA mutant (Fig. 1). In UTI89 infection,
there was one invasion event per 100 bound cells, while infection with UTI89 surA::kan resulted in one invasion event per
1,000 bound cells. These defects in binding and invasion were
complemented with an episomal copy of surA under the control of the ParaBAD promoter.
Distribution of FimH adhesin in UTI89 surA::kan. The decreased invasion efficiency of the surA mutant could result
from reduced levels of functional pili and/or reflect a requirement for additional SurA-dependent proteins for invasion. In
order to evaluate the presence of FimH, bacteria were studied
by immunofluorescence microscopy using a mouse antibody
raised to the FimH adhesin domain (FimHA). After overnight
static growth, a substantial proportion of wild-type bacteria
were labeled with anti-FimHA, while labeling of surA mutant
bacteria was not detected using this approach (Fig. 2A and D).
Next, the density of pili on the bacterial surface was evaluated
by negative-stain EM. The majority of wild-type UTI89 bacteria were piliated (Fig. 2B), and immunolabeling with antiFimHA antibody confirmed that these fibers were type 1 pili
(Fig. 2C). By negative-stain EM, the majority of surA mutant
bacteria were bald or sparsely piliated (Fig. 2E). In addition,
approximately 10% of the bacteria produced distinct, bundledlooking fibers that did not react with the anti-FimHA anti-
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FIG. 2. Microscopy of surA mutant UPEC. Immunofluorescence of an overnight static culture of UTI89 demonstrates type 1 piliation (A),
while UTI89 surA::kan is not labeled with anti-FimHA antibody (D). Negative-stain EM reveals that, in contrast to wild-type UTI89 (B), the
majority of UTI89 surA::kan bacteria are nonpiliated (E). Immunogold EM with anti-FimHA antibody identifies type 1 pili on the surface of UTI89
(C) but does not consistently label the thicker, bundled fibers (arrow) expressed by a minority of surA mutant bacteria (F). Scale bars, 200 nm.
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FIG. 3. In vivo invasion is intact in the UTI89 surA mutant complemented with pDH15 in an ex vivo gentamicin protection assay.
C3H/HeN female mice were transurethrally inoculated with wild-type
UTI89, UTI89 surA::kan, or UTI89/pDH15 surA::kan, and bladders
were harvested after 1 h and processed as described in Materials and
Methods. Luminal bacteria and invaded bacteria (intracellular) were
quantified by serial dilution and plating. UTI89 surA::kan persists
poorly in the lumen over 1 h of infection and invades poorly compared
to wild-type UTI89 (*, P ⬍ 0.005); complementation with pDH15
restores early luminal colonization and invasion to wild-type levels.
Experiments were repeated at least three times with similar results.

serum (Fig. 2F). The nature of these fibers is under investigation. It is presumed that the sparse residual pili of surA mutant
bacteria are responsible for the minimal HA and in vitro binding activity of UTI89 surA::kan. Decreased pilus density may
contribute to the additive invasion defect in UTI89 surA::kan;
however, the requirement for alternative, SurA-dependent factors that enhance invasion cannot be excluded.
UTI89 surA::kan is deficient in establishing murine cystitis.
Although type 1 pili are required for binding and invasion of
bladder epithelial cells in vivo (18), a role for type 1 pili or any
other bacterial protein during IBC maturation (i.e., following
invasion) has not been established. In addition, other substrates for SurA may be important in intracellular development. To examine the in vivo requirements for SurA during
uropathogenesis, the course of murine cystitis with UTI89
surA::kan was studied. Female C3H/HeN mice were transurethrally inoculated with ⬃107 CFU of wild-type UTI89, UTI89
surA::kan, or UTI89 surA::kan complemented with a plasmid
carrying surA under the control of the arabinose promoter
(pDH15). A gentamicin protection assay was used to verify
that pDH15 complemented the binding and invasion defect of
UTI89 surA::kan in vivo. Bladders were removed at 1 hour and
washed in 1 ml PBS to collect the luminal bacteria. Significant
numbers of luminal bacteria were observed in UTI89 and

UTI89/pDH15 surA::kan infections, while the surA mutant had
been largely eliminated (Fig. 3, luminal). Intracellular bacteria
were enumerated following gentamicin treatment and subsequent bladder homogenization. UTI89 and UTI89/pDH15
surA::kan invaded at nearly the same levels, but UTI89
surA::kan was invasion deficient (Fig. 3, intracellular).
Because murine tissues lack L-arabinose, the complemented
strain UTI89/pDH15 surA::kan was ideally suited for investigation of the requirement for SurA substrates in vivo at time
points reflecting intracellular growth, IBC maturation, and
bacterial persistence. Bladders were harvested and homogenized in order to enumerate the bacterial load. Wild-type
UTI89 colony counts averaged 106 CFU/bladder over the first
48 h of infection and persisted at 2 weeks after infection (Fig.
4). Bladder colony counts of UTI89 surA::kan were significantly lower over the first 48 h, an interval marked by intracellular growth in wild-type infection (16). The surA mutant
was nearly eliminated by 2 weeks, further suggesting that substrates for SurA are required for intracellular growth and progression through IBC maturation and establishment of a
chronic reservoir. Provision of surA in trans on plasmid pDH15
failed to restore wild-type bladder colony counts at time points
⬎48 h (data not shown). The inability of pDH15 to complement colonization was presumably related either to reduction
in plasmid copy number or to in vivo depletion of SurA due to
the absence of arabinose in the animal chow and low levels of
arabinose uptake by rodent cells (9). Recovered bacteria remained resistant to ampicillin, indicating the plasmid was retained (data not shown).
To determine whether the few recoverable intracellular surA
mutant bacteria represented multiple invasion events not proceeding through the IBC cascade or limited IBC formation
from a very few invasion events, bladders were visualized microscopically, taking advantage of the observation that UTI89
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FIG. 4. The UPEC surA mutant is deficient in establishing murine
cystitis. Mice were infected with the wild type or UTI89 surA::kan and
the bladders harvested for titers at the indicated time points. Wild-type
UTI89 persists at 106 CFU/bladder during the first 48 h of infection,
while UTI89 surA::kan titers fall off and are nearly undetectable at 2
weeks after infection. Titers of UTI89 surA::kan are significantly lower
than those of wild-type UTI89 at all time points (ⴱ, P ⬍ 0.0001; ⴱⴱ, P ⬍
0.001). Horizontal bars indicate mean titers. Experiments were repeated at least three times.
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is lacZ⫹. To assess the number of IBCs, female C3H/HeN mice
were infected transurethrally with UTI89, UTI89 surA::kan, or
UTI89/pDH15 surA::kan and mice were sacrificed 6 h after
infection. Bladders were harvested aseptically, fixed in 10%
neutral buffered formalin, and stained with an X-Gal-containing substrate. Infection with wild-type UTI89 yielded a range
of 20 to 210 IBCs per bladder (Fig. 5A), while no IBCs were
detected in bladders infected with UTI89 surA::kan (Fig. 5B).
Similarly, no IBCs were detected using this method when surA
was provided in trans on plasmid pDH15 (data not shown).
Histologic examination of the same bladders confirmed the
whole-mount lacZ staining results, demonstrating the presence
of IBCs after wild-type infection (Fig. 5C), while neither the
UTI89 surA::kan-infected (Fig. 5D) nor UTI89/pDH15 surA::
kan-infected (not shown) bladders demonstrated IBCs.
SurA is essential for intracellular growth and morphological transition. UTI89/pDH15 surA::kan bacteria, though successful at initial invasion, failed to progress to mature IBCs as
determined by light microscopy. Thus, to dissect the apparent
need for SurA substrates during IBC maturation, we examined
the morphology of IBCs by fluorescence confocal microscopy.
Female C3H/HeN mice were inoculated with UTI89 or UTI89
surA::kan transformed with pcomGFP or UTI89/pDH15 surA::
kan, and bladders were harvested and viewed 6 and 16 h after

inoculation. When compared to wild-type UTI89, establishment of IBCs was sharply impaired in UTI89 surA::kan (Fig.
6). Consistent with previous studies (2, 16), UTI89 formed
early IBCs of loose, rod-shaped bacteria at 6 h, which had
progressed to larger collections of tightly packed, coccoid bacteria by 16 h (Fig. 6A and D). No bacteria were observed in
most bladders infected with UTI89 surA::kan at either of these
time points (not shown). However, a few isolated surfacebound surA mutant bacteria (Fig. 6B) were occasionally seen at
6 h, and in one instance a loose intracellular collection of ⬃20
surA mutant bacteria was observed at 16 h (Fig. 6E). Examination of the UTI89/pDH15 surA::kan-infected bladders confirmed a failure to carry out the IBC program. At 6 h, very
small loose collections of intracellular UTI89/pDH15
surA::kan bacteria were observed in a small number of superficial facet cells (Fig. 6C). At 16 h, limited intracellular bacterial growth had taken place but bacterial density and morphology were still significantly reduced compared to that seen in
wild-type UTI89 infection. Specifically, intracellular collections
of UTI89/pDH15 surA::kan bacteria did not assume the tightly
packed, coccoid morphology typical of mature wild-type IBCs
(compare Fig. 6F to D). Of note, UTI89 surA::kan demonstrated no growth defect in Luria broth culture when compared
to the wild type (data not shown).
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FIG. 5. The UPEC surA mutant fails to establish IBCs. C3H/HeN mice were inoculated with wild-type UTI89, UTI89 surA::kan, or UTI89/
pDH15 surA::kan; bladders were harvested at 6 h after infection and exposed to an X-Gal-containing substrate (see Materials and Methods). In
whole mount, wild-type IBCs are visible as dark blue spots on the bladder surface (A), while UTI89 surA::kan (B) infection yields no such staining.
By light microscopy, UTI89-infected bladders contain IBCs; panel C includes an example in which deparaffinization incompletely removed the lacZ
stain from an IBC. Bladders infected with UTI89 surA::kan (D) or UTI89/pDH15 surA::kan (not shown) contain no developed IBCs. Experiments
were repeated at least three times.
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DISCUSSION
Protein folding in the periplasm of gram-negative bacteria is
accomplished via a set of ATP-independent catalysts, including
disulfide bond isomerases (e.g., DsbA), pilus chaperones (e.g.,
PapD), and PPIases. The PPIases include PpiA, PpiD, FkpA,
and SurA, all of which display homology to members of immunophilin families in eukaryotes. In E. coli K-12, SurA is
unique among the prolyl isomerases in that surA mutants display increased membrane permeability and sensitivity to certain antibiotics and dyes (19, 28). In addition, a surA mutation
is synthetically lethal with mutations in genes encoding the
chaperone Skp or the periplasmic protease DegP, suggesting
that SurA functions in parallel with these chaperones in the
periplasm (26). A quadruple mutant in all of the four PPIases
in E. coli K-12 remains viable but has a mild growth defect and
is unable to assemble pili via the chaperone/usher pathway
(17). In this study, we discovered that SurA plays critical roles
in the intracellular lifestyle of UTI pathogenesis.
The role of SurA in binding and invading bladder epithelial
cells was investigated using a human bladder carcinoma cell
line. Consistent with previous studies with E. coli K-12 (17), the
chromosomal surA mutation in the clinical isolate UTI89

sharply reduced but did not abolish type 1 piliation. In addition, a small subpopulation of surA mutant bacteria produced
thicker, bundled appendages that did not label consistently
with anti-FimHA antibody by immunogold EM, suggesting that
disruption of surA results in altered pilus regulation. UTI89
surA::kan exhibited a corresponding 10-fold reduction in ability to bind to cultured cells, but, surprisingly, when invaded
bacteria were quantified as a proportion of bound bacteria,
UTI89 surA::kan showed an additional 10-fold defect in invasion. Thus, FimH-mediated binding to bladder epithelial cells
is necessary but may not be sufficient for bacterial invasion.
These data argue that either a threshold number of type 1 pili
are necessary to mediate invasion or that an alternative substrate for SurA is involved in potentiating invasion.
In a well-characterized model of murine cystitis, UTI89
surA::kan was severely attenuated and was eliminated from the
urinary tract by 2 weeks postinfection, in contrast to wild-type
UTI89, which forms a persistent intracellular reservoir (24).
Using an in vivo gentamicin protection assay, we discovered
that UTI89 surA::kan invaded the bladder epithelium 100-fold
less efficiently than wild-type UTI89. This reduced level of
bacterial invasion, while still detectable, did not lead to IBC
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FIG. 6. SurA is required for IBC maturation. UTI89/pcomGFP, UTI89/pcomGFP surA::kan, and UTI89/pDH15 surA::kan were used to
inoculate C3H/HeN female mice, and the bladders were viewed in whole mount by confocal microscopy at 6 h (top row) and 16 h (bottom row).
UTI89 forms early IBCs at 6 h (A) and matures into tightly packed coccoid IBCs by 16 h (D), while the UTI89 surA mutant fails to establish
intracellular growth (B). At 16 h, a single collection of ⬃20 intracellular bacteria was seen in one of ⬎20 bladders infected with UTI89 surA::kan
across several replicated experiments (E). Complementation of type 1 piliation in vitro and binding and invasion in vivo via the plasmid pDH15
permit invasion and modest intracellular replication by 6 h (C), but UTI89/pDH15 surA::kan IBCs do not mature properly by 16 h (F),
demonstrating lower density, looser organization, and persistent rod-shaped bacterial morphology compared to wild-type IBCs.
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FIG. 7. Model depicting the contributions of SurA to steps in the
UPEC pathogenic cascade. SurA supports binding and invasion of bladder epithelial cells through type 1 pilus assembly. In addition, other SurA
substrates may potentiate invasion. SurA activity is required for intracellular growth of UPEC and for maturation of IBCs. Finally, suppression of
bladder epithelial cytokines in vitro also requires SurA (15), which may
impact bacterial persistence (dashed line).

This work was supported by National Institutes of Health grants F32DK10168 (S.S.J.); P50-DK64540, R01-DK51406, and R01-AI29549
(S.J.H.); and K08-DK067894 (D.A.H.).
We thank W. Beatty for microscopy, P. Seed for technical advice,
and T. Silhavy for helpful discussions.

formation by UTI89 surA::kan, as determined by whole-mount
lacZ staining and by fluorescence microscopy. Complementation of UTI89 surA::kan with pDH15 (surA) restored the early
binding and invasion events in vivo; wild-type and UTI89
surA::kan CFU recovered from infected bladders treated with
gentamicin were similar at 1 hour postinfection. However, due
to the absence of the arabinose inducer within the mouse
bladder, surA expression was thought to be lost during the
course of UTI89/pDH15 surA::kan infection, and we discovered that IBC formation by UTI89/pDH15 surA::kan was defective. In contrast to wild-type IBCs, the intracellular collections of UTI89/pDH15 surA::kan seen at 6 and 16 h contained
fewer bacteria, were loosely organized, and lacked the normal
transition to a densely packed, coccoid morphology. Thus,
SurA in UPEC acts on substrates that are required for IBC
maturation. Further, in vitro growth of UTI89 surA::kan was
equivalent to wild type, suggesting that the intracellular environment uniquely requires SurA function for bacterial growth.
We propose that the conserved periplasmic chaperone SurA
supports UPEC virulence and the IBC cascade in multiple
ways (Fig. 7). SurA activity clearly underlies type 1 pilus assembly (17) and, in turn, the ability of UPEC to bind to and
invade bladder epithelial cells, both in vitro and in vivo. In this
study, we have demonstrated that the intracellular phenotype
of SurA depletion includes deficient growth, persistent bacillary morphology, and failure of persistence, suggesting that
IBC maturation is critical in UTI pathogenesis and requires
substrates of SurA. Subsequent to bacterial invasion, it is unclear what role, if any, type 1 pili would play in these processes.
The adverse effect of surA disruption on intracellular growth
and IBC maturation may result from effects on interbacterial
sensing mechanisms, nutrient acquisition pathways, or other
surface factors, including the products of a multitude of chaperone-usher pathways found in UPEC (5). Identification of
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